Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA in Patients after Cataract Surgery
SHANGHAI, Oct. 31, 2023. AffaMed Therapeutics ( " AffaMed " ), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Biotechnology | Cataract Removal | Cataracts | China Health | Clinical Trials | Information Technology | Pharmaceuticals | Study